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Liver transplantation in Australia 
I n the United States, a means has been in place for several years to assist the transition of new treatment technologies from the 
status of experimental to "service". The mechanism is a forum 
called the Consensus Development Conference, at which the 
proponents and the critics of the treatment in question have their 
say. Adjudication of the merits of these arguments is by a panel of 
experts, consumer advocates, and health-care planners. The meetings 
last for two or three days, are open to the public, and their 
proceedings are published eventually. 
On June 20-23, 1983, liver transplantation was subjected to this 
evaluation in Bethesda, Maryland, at the suggestion of the Surgeon 
General of the United States, Dr C. Everett Koop. The conclusions 
were unequivocal, as based on evidence and experience in the United 
States and Europe. Liver transplantation was found unanimously . 
to be an effective treatment for many end-stage hepatic diseases. 
and under reasonably definable conditions. In fact, liver replacement 
was the only kind of therapy which was not a waste of resources 
in some circumstances. The proceedings of this Consensus 
Development Conference were published in a supplement to 
Hepatology in January, 1984,1 and its conclusions have been accepted 
without change by the Organ Transplant Council of the American 
Medical Association. 
In view of the foregoing events. the bitterly critical nature of an 
editorial' about liver transplantation in The Medical Journal 0/ 
Australia was difficult to understand since it was written more than 
a year after the Consensus Development Conference. and nine 
months after the deliberations of that conference had become known 
widely. Nevertheless, two vital and successful liver transplantation 
programmes have now sprung up in Australia - one in Sydney and 
the other in Brisbane - and their initial reports are published in 
this issue of the Journal (page 372 and page 380). 
In both cases, a remarkable degree of thought and preparation 
preceded the initial trials. The leader of the Sydney programme, 
Professor Ross Shiel, was one of the world pioneers in renal trans-
plantation, and one of the earliest contributors to the then fledgling 
procedure of liver transplantation 20 years previously. Several 
members of the Queensland team had spent extended periods (as 
long as two years) at the University of Pittsburgh liver transplant 
centre. 
When liver transplantation was first performed successfully in 
1967, the results were unpredictable with an overwhelming mortality 
in the first postoperative year!.Since the introduction of cyclosporin 
A-corticosteroid therapy in 1980, the survival has more than tripled.' 
However, even from the earliest cases, it was learned that a relatively 
normal life could be restored to victims of end-stage liver disease. 
The longest surviving patient in the world today was four years old 
at the time of her transplantation. Now in her 18th postoperative 
year, she is married to a US marine and lives in Japan. Many 
survivors of the earlier era have now lived beyond 10 years.s A 
substantial number have become parents of their own children. The 
long-term durability of functioning liver grafts has seemed to be 
greater than that of functioning cadaver kidney transplants. 
In the previous editorial in this Journal,l it was suggested that 
high-intensity care, such as liver transplantation, for hopelessly-ill 
patients was not only costly, but that it was inhumane when all that 
was achieved was the prolongation of painful dying. This possibility 
is so important that it deserves thoughtful examination. However, 
study of the long-surviving recipients of liver grafts has demonstrated 
repeatedly that complete rehabilitation can be achieved in the 
majority of cases.'·" 
It has been said that society and its institutions are judged by 
the way that they treat those who cannot defend themselves, as 
exemplified by the mortally-ill. In the past, what could be done for 
hopelessly-ill patients was all too often non-specific. Transplantation 
has changed this. With liver-grafting procedures. the high cost of 
treatment often has been decried by critics, who have had no 
objection to the expensive care that is required for patients who 
become invalids and hospital-bound by their hepatic disease. Their 
objections are to the only treatment that is capable of the liberation 
of these patients from hospital life, of their restoration to life in 
society, and of putting an end to a continuous accrual of expenses 
down a therapeutic cul-de-sac. 
It is conceivable, but highly unlikely, that some day society will 
decide that no patient will be treated who is suffering from liver 
disease, or from diseases of certain other organ systems, such as the 
heart or kidney. If so, the argument that is cited in the preceding 
paragraph will have great force, and physicians (those who are left) 
will want to determine the cheapest way to exercise what will have 
become a priestly, not a therapeutic, function. Until then, the proper 
first decision by those who serve society will be whether treatment 
should be carried out. If the answer is "yes", the appropriate second 
question will be: "What is the best way?". Then, what will be 
purchased per health-care dollar will be real, not symbolic. 
Developments in transplantation and artificial organ technology 
have changed forever the philosophy by which organ-defined 
specialties, such as nephrology, hepatology and cardiology, are 
practised. Until recently, what could be offered to victims of vital-
organ failure was a rearguard approach, with diet, medicines or 
surgical procedures, that was designed to extract the last moment 
of life-supporting function from the failing organ. Now - and for 
the first time in human history - the breath-taking possibility has 
emerged, when all else fails, of starting over with an organ graft 
or with a manufactured organ. 
Failure to take advantage of these developments, and failure to 
exploit such new possibilities, is like giving birth to a beautiful child 
and then trying to starve it for specious reasons so that it will not 
threaten the food supply. The Australian liver transplant programmes 
are in good hands. For a country which already has such exceptional 
standards in health care as Australia, the following message will be 
superfluous. But for what it is worth, your American cousins wish 
you good luck. THOMAS E. STARZL 
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